Track Syros Pharmaceuticals, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Syros Pharmaceuticals, Inc. SYRS · Stock Open Syros Pharmaceuticals, Inc. in new tab

0.000100 USD
EPS
-6.14
P/B
0.00
ROE
-776.96
Beta
1.79
Target Price
8.75 USD
Loading chart...
Key Metrics
Earnings dateMarch 31, 2027
EPS-6.14
Book Value-0.42
Price to Book0.00
% Insiders0.075%
Estimates
Forward P/E0.00
Forward EPS-2.61
Target Mean Price8.75

DCF valuation

Model fair value for Syros Pharmaceuticals, Inc. (SYRS)
Result
Sign in to run the valuation for SYRS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
4 analysts · consensus None · mean target 8.75 USD (low 4.00, high 20.00) · as of 9 Nov 2026
Low 4.00
Mean 8.75
High 20.00
Price 0.000100
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Syros Pharmaceuticals, Inc. Logo Syros Pharmaceuticals, Inc. Analysis (SYRS)

United States Health Care Official Website Stock

Is Syros Pharmaceuticals, Inc. a good investment? Syros Pharmaceuticals, Inc. (SYRS) is currently trading at 0.000100 USD. Market analysts have a consensus price target of 8.75 USD. This suggests a potential upside from current levels.

Earnings Schedule: Syros Pharmaceuticals, Inc. is expected to release its next earnings report on March 31, 2027. The market consensus estimate for Forward EPS is -2.61.

Investor FAQ

Does Syros Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Syros Pharmaceuticals, Inc.?

Syros Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 31, 2027. The company currently has a trailing EPS of -6.14.

Company Profile

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Exchange Ticker
NMS (United States) SYRS
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Sept. 19, 2022 1:10
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion